Atsena Therapeutics

Biotechnology Research • United States • 21-50 Employees

Company overview

Headquarters	United States
Phone number	+13522739342
Website	atsenatx.com
Employees	21-50
Socials

Key Contacts at Atsena Therapeutics

Jae Ahn

Director Of Biostatistics, Data Management, And Programming

Rob Hallford

Senior Director Business Development

Bryan Troxell

Sr. Director Analytical Development

Joe Zakrzewski

Chairman, Board Of Directors

Dan Yoon

Senior Medical Director

Alexander Gottlieb

Director, Cmc Operations

Stephanie Cush

Sr. Director, Alliance & Program Management

Lola Fong

Director Of Clinical Operations

Laura Pardon

Associate Director, Clinical Development

Atsena Therapeutics Email Formats

Atsena Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@atsenatx.com), used 65% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@atsenatx.com	65%
{first name}.{last name}	john.doe@atsenatx.com	35%

About Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company’s lead program is evaluating ATSN-201 in an ongoing Phase 1 / 2 / 3 clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. ATSN-101, Atsena’s first-in-class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), has completed a Phase 1 / 2 trial with positive results (https://doi.org/10.1016/s0140-6736(24)01447-8). Atsena is advancing ATSN-101 toward the initiation of a global pivotal trial as part of its exclusive strategic collaboration with Nippon Shinyaku Co., Ltd. Atsena’s pipeline is powered by novel adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal diseases. Founded by pioneers in ocular gene therapy, Atsena is led by an experienced team dedicated to addressing the needs of patients with vision loss.

Atsena Therapeutics revenue & valuation

Annual revenue	$15,000,000
Revenue per employee	$469,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$48,000,000
Total funding	$174,500,000

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Senior

Director

Vice President

Employees by Department

Atsena Therapeutics has 9 employees across 5 departments.

Departments

Number of employees

Funding Data

Explore Atsena Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-11-02	1	$24,500,000
2025-05-02	6	$150,000,000

Funding Insights

$174,500,000

Total funding amount

$150,000,000

Most recent funding amount

Number of funding rounds

Atsena Therapeutics Tech Stack

Discover the technologies and tools that power Atsena Therapeutics's digital infrastructure, from frameworks to analytics platforms.

MediaElement.js

Video players

Cloudflare Bot Management

Security

Microsoft 365

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

HTTP/3

Miscellaneous

PHP

Programming languages

WordPress

Blogs

Yoast SEO

SEO

GoDaddy

Hosting

Frequently asked questions

Atsena Therapeutics is located in US.

You can reach Atsena Therapeutics at +13522739342.

Atsena Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Atsena Therapeutics has raised a total of $174,500,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.